| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss attributable to nexgel stockholders | NaN | NaN | -653 | -1,377 |
| Realized gain on investment in marketable securities | NaN | 0 | 0 | 0 |
| Net changes in operating lease assets and liabilities | NaN | NaN | 0 | 21 |
| Change in fair value of contingent consideration | NaN | 0 | NaN | NaN |
| Change in fair value of warrant liability | NaN | -6 | -8 | -104 |
| Income (loss) attributable to non-controlling interest in joint venture | NaN | NaN | 6 | 59 |
| Net loss | -871 | -2,893 | NaN | NaN |
| Depreciation and amortization | 99 | 112 | 113 | 225 |
| Share-based compensation and restricted stock vesting | 143 | 156 | 205 | 293 |
| Amortization of right-of-use asset | 73 | 290 | NaN | NaN |
| Gain in spin-off of nexgelrx | NaN | 162 | NaN | NaN |
| Amortization of debt discount | 11 | NaN | NaN | NaN |
| Accounts receivable, net | -11 | -166 | 86 | -180 |
| Inventory | 152 | 92 | 198 | 70 |
| Prepaid expenses and other assets | 95 | -390 | 23 | 240 |
| Accounts payable | 479 | -72 | -31 | 65 |
| Accounts payable related party | 38 | 145 | -26 | -84 |
| Deferred revenue | NaN | -178 | 0 | 1 |
| Accrued expenses and other current liabilities | -32 | -70 | -4 | 224 |
| Partnership advance | -135 | 811 | -80 | NaN |
| Operating lease liability | -73 | -260 | NaN | NaN |
| Net cash used in operating activities | -504 | 281 | -785 | -807 |
| Investment in subsidiary | NaN | 0 | NaN | NaN |
| Proceeds from sales of marketable securities | NaN | 0 | 0 | 0 |
| Net cash paid for asset acquisition | NaN | NaN | 0 | 0 |
| Purchases of equipment | NaN | 68 | NaN | NaN |
| Capital expenditures | -19 | NaN | 8 | 20 |
| Net cash used in investing activities | -9 | -40 | -8 | -20 |
| Proceeds from non-controlling interest | NaN | 0 | NaN | NaN |
| Proceeds from margin line of credit | NaN | 0 | 0 | NaN |
| Investment by joint venture partner | NaN | NaN | 0 | 0 |
| Change in contingent consideration liability | NaN | NaN | 0 | NaN |
| Proceeds from stada (note 17) | NaN | NaN | 1,000 | NaN |
| Proceeds from rights offering | NaN | -92 | 1,055 | 0 |
| Stock issuance costs | NaN | NaN | 92 | NaN |
| Payment of contingent consideration | NaN | -1 | 0 | 178 |
| Proceeds from convertible notes payable, net | 1,618 | NaN | NaN | NaN |
| Principal payment on financing lease liability | 16 | 16 | 14 | 29 |
| Principal payments of notes payable | 25 | 26 | 23 | 48 |
| Net cash provided by (used in) financing activities | 1,577 | -1,041 | 1,926 | -255 |
| Net increase (decrease) in cash () | NaN | -800 | NaN | NaN |
| Net increase (decrease) in cash | 1,064 | -800 | 1,133 | -1,082 |
| Cashand restricted cash beginning of period | 1,058 | 1,858 | 1,807 | NaN |
| Cash and restricted cash end of period | 2,122 | 1,058 | 1,858 | NaN |
NEXGEL, INC. (NXGLW)
NEXGEL, INC. (NXGLW)